Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment

Clinical and Experimental Rheumatology

Volumn 28, Issue 6, 2010, Pages 800-803

  Derdemezis, C S ^a   Filippatos, T D ^a   Voulgari, P V ^b   Tselepis, A D ^b   Drosos, A A ^b   Kiortsis, D N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adiponectin; Ankylosing spondylitis; Infliximab; Leptin; TNF

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; ENZYME IMMUNOASSAY; ERYTHROCYTE SEDIMENTATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 79958110293     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. TILG H, MOSCHEN AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83.
2. LAGO F, DIEGUEZ C, GÓMEZ-REINO J, GUALILLO O: Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007; 3: 716-24.
3. MATSUZAWA Y, FUNAHASHI T, KIHARA S, SHIMOMURA I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vase Biol 2004; 24: 29-33.
4. DERDEMEZIS CS, FILIPPATOS TD, VOULGARI PV, TSELEPIS AD, DROSOS AA, KIORTSIS DN: Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam Clin Pharmacol 2009; 23: 595-600.
5. KIDD BL, CAWLEY MI: Delay in diagnosis of Spondarthritis. Br J Rheumatol 1988; 27: 230-2.
6. ALAMANOS Y, PAPADOPOULOS NG, VOULGARI PV, KARAKATSANIS A, SIOZOS C, DROSOS AA: Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. Rheumatology (Oxford) 2004; 43: 615-8.
7. BRAUN J, DAVIS J, DOUGADOS M, SIEPER J, VAN DER LINDEN S, VAN DER HEIJDE D; ASAS WORKING GROUP: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-20.
8. SIDIROPOULOS PI, SIAKKA P, PAGONIDIS K et al: Sustained improvement of vascular endothelial function during anti-TN Falpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009; 38: 6-10.
9. KIORTSIS DN, MAVRIDIS AK, VASAKOS S, NIKAS SN, DROSOS AA: Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-6.
10. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
11. CALIN A, GARRETT S, WHITELOCK H et al: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
12. VAN DER HEUDE D, LANDEWE R, FELDTKELLER E: Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2step and 10-step definitions. Ann Rheum Dis 2008; 67: 489-93.
13. KIORTSIS DN, MAVRIDIS AK, FILIPPATOS TD, VASAKOS S, NIKAS SN, DROSOS AA: Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006; 33: 921-3.
14. TEMEKONIDIS TI, ALAMANOS Y, NIKAS SN et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62: 1218-20.
15. Sari I, Demir T, Kozaci LD et al: Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 1427-32. (Pubitemid 47193559)
16. PARK MC, LEE SW, CHOI ST, PARK YB, LEE SK: Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 2007; 36: 101-6.
17. PARK MC, CHUNG SJ, PARK YB, LEE SK: Proinflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis. Joint Bone Spine 2009; 76: 170-5.
18. Toussirot E, Streit G, Nguyen NU et al.: Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 2007; 56: 1383-9. (Pubitemid 47404601)
19. OTERO M, LAGO R, GOMEZ R et al.: Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-201.
20. LAURBERG TB, FRYSTYK J, ELLINGSEN T et al.: Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol 2009; 36: 1885-91.
21. GILES JT, ALLISON M, BINGHAM CO 3RD, SCOTT WM JR, BATHON JM: Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2009; 61: 1248-56.
22. CHOI HM, LEE YA, LEE SH et al.: Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res Ther 2009; 11: R161.
23. Peters MJ, Welsh P, Mcinnes IB et al.: Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 2010; 69: 1687-90.
24. GONZALEZ-GAYMA.GARCIA-UNZUETAMT, BERJAA et al.: Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 222-8.
25. HÄRLE P, SARZI-PUTTINI P, CUTOLO M, STRAUB RH: No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 970-1.
26. TOUSSIROT E, STREIT G, WENDLING D: The contribution of adipose tissue and adipokines to inflammation in joint diseases. Curr Med Chem 2007; 14: 1095-100.